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Summary It is now clearly established that proteolytic enzymes, including plasminogen activator (uPA), play
an important role in breaking down the extracellular matrix, which is considered to be a step in metastasis
formation. Plasminogen activators are controlled at various levels. Two inhibitors, PAI- 1 and PAI-2, have
been identified, the latter being more specific for uPA. In attempts to determine their prognostic value, it is
essential to investigate the relative importance of these parameters and their interactions. We used an
immunoenzymatic method to assay uPA, PAI-I and PAI-2 antigens in cytosols prepared from 314 primary
breast tumours. The patients were followed up for a minimum of 6 years and all relevant clinical and
laboratory findings were recorded. Univariate analysis confirmed the poor outcome of patients whose tumours
contained large amounts of uPA and PAI-1. In addition, low levels of PAI-2 correlated with shorter
disease-free survival in the overall population (P= 0.02), post-menopausal women (P= 0.02) and women
without lymph node involvement (P = 0.02). Multivariate analysis in the 'main effects' Cox model identified
node involvement, macroscopic tumour size and PAI-2 as significant variables. The 'interactive' model, taking
into account interactions between uPA and its two inhibitors, identified a first subgroup with a very poor
prognosis associating either high levels of PAI-I with low levels of PAI-2 in the overall population and the
women with no node involvement or high levels of uPA with low levels of PAI-2 in the group of menopausal
women. We conclude that PAI-I provides the same prognostic information as uPA, and does not appear to
play a role as an inhibitor. In contrast, PAI-2 increases the prognostic value of uPA, particularly in
post-menopausal women, and PAI- 1 in patients with no node involvement.
Tumour cell invasion and metastasis formation is a multifac-
torial process. The remodelling it involves requires the coor-
dinated action of cell-secreted proteolytic enzymes and their
inhibitors. Elevated levels of urokinase-type plasminogen
activator (uPA) have been implicated in these invasive pro-
cesses (Dano et al., 1985; Duffy, 1987; Layer et al., 1987;
Markus et al., 1988; Pyke et al., 1991b), and plasminogen
activator inhibitor type 1 (PAI-1) has been found in many
types of malignant tissue (Kruithof et al., 1988; Cubellis et
al., 1990; Foucre et al., 1991; Tanaka et al., 1991; Reilly et
al., 1992). Plasminogen activator inhibitor type 2 (PAI-2) is
one of the primary physiological inhibitors of uPA. Individ-
ual prognostic values have been reported in breast cancer
(Duffy et al., 1990; Janicke et al., 1990, 1993; Grondahl-
Hansen et al., 1992; Spyratos et al., 1992; Sumiyoshi et al.,
1992). The purpose of this study was to analyse the antigen
levels of uPA, PAI-l and PAI-2 by means of an enzyme-
linked immunosorbent assay (ELISA) technique and to
evaluate their relative value in predicting disease-free and
metastasis-free survival rates of primary breast cancer
patients.
Materials and methods
Patients
The 314 patients in this study (mean age 55 years; range
30-86 years) were selected according to the following
criteria: primary, unilateral breast carcinoma and treatment
at the Centre Rene Huguenin between 1980 and 1985. The
median follow-up was 7 years (maximum 11 years) at the
time of the study. Fifty-nine per cent of patients had under-
gone a total mastectomy and 41% of patients a partial
mastectomy; both groups had undergone axillary lymph node
clearance. Two hundred and three patients had received post-
operative irradiation. Patients (n = 115) regarded as high risk
[i.e. those with more than three involved axillary lymph
nodes or those with at least one involved axillary lymph node
and Scarff, Bloom and Richardson (SBR) (Bloom &
Richardson, 1957; Scarff & Torloni, 1968) histological grade
III tumours and those aged below 35 years] had received
post-operative chemotherapy or hormone therapy. All
patients received peroperative thiotepa. Two hundred and
ninety-two patients underwent clinical, radiological and
laboratory tests every 3 months for the first 2 years and
yearly thereafter. At the time of analysis, 91 patients had
relapsed (37 had recurrences, 78 had distant metastases); of
these, 54 died of breast cancer.
Tissue extract samples
Tumour specimens were obtained at surgery, selected by the
pathologist and stored in liquid nitrogen until extraction.
Age, SBR histological grade, number of involved lymph
nodes (mean number of lymph nodes examined = 14; range
7-40), macroscopic tumour size, menopausal status and oest-
rogen and progesterone receptor status (EORTC, 1980) were
known in every case (Table I). For extraction, tissues pieces
of 250-300 mg wet weight were pulverised at 4°C in
10 mm Tris-HCl buffer pH 7.4 containing 1.5 mM EDTA,
0.5 mM dithiothreitol and 10% glycerol. The suspension was
centrifuged (100,000 g at 4°C for 60 min). The cytosols were
collected and stored in liquid nitrogen until use.
Assay ofuPA, PAI-I and PAI-2
Levels of uPA, PAI-I and PAI-2 antigen were measured in
cytosols by an immunoenzymatic method (Biopool Tint
Elize, Umea, Sweden). Monoclonal anti-uPA antibody was
raised against pro-uPA, two forms of uPA (low and high
molecular weight) and uPA bound to plasminogen activator
inhibitor type 1 or 2 (PAI-I or PAI-2). Monoclonal anti-
PAI-I antibody recognises active and inactive forms of PAI-I
and PAI-I bound to uPA or tPA. Monoclonal anti-PAI-2
antibody recognises low molecular weight PAI-2 (44.6 kDa)
and glycosylated high molecular weight PAI-2 (60 kDa).
After incubation of cytosols for 2 h at 25°C with agitation,
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the second polyclonal antibody labelled with peroxidase was
added. Absorbance was measured at 405 nm in a microtitre
plate reader (Milenia Kinetic Analyser). Antigen levels
(ngml') were obtained from standard curves. Protein levels
(mean= 1.8 ng ml-1) were assayed using the Bradford
method (Bradford, 1976; Bio Rad, CA, USA). Results were
expressed in ng per mg of protein-and assays were performed
in triplicate. The Biopool Tint Elize Kit commercial stan-
dards for sera were optimised by diluting cytosols (1:6 for
the assay of PAI-I and 1:2 for PAI-2) in phosphate-buffered
saline (PBS) solution pH 7.4, EDTA/Tween 20, containing
bovine serum albumin (BSA) 1:1,000. The detection limit is
about 0.1 ng ml-' for uPA, 2.5 ng ml' for PAI-I and
4.0 ng ml-' for PAI-2.
Statistical methods
Differences in the distribution of characteristics among
patient subgroups were analysed using the x2 test. Spearman
correlation coefficients (p) were computed for pairwise com-
binations of uPA, PAI-1, and PAI-2. The cut-off points for
uPA, PAI-i and PAI-2 were determined independently of
prognosis by the K-means clustering method (Hartigan,
1975), which separates patients into clusters so that the
within-cluster sum of squares is minimised. For each
parameter, actuarial disease-free survival (DFS) and
metastasis-free survival (MFS) rates were calculated accord-
ing to the method of Kaplan and Meier (1958) and compared
by the log-rank test. DFS was defined as the time from
diagnosis to the detection of the first local relapse or distant
metastasis, and MFS was defined as the time from diagnosis
to the occurrence of the first distant metastasis (locoregional
relapse was excluded) or to the end of the study. A forward
stepwise multivariate Cox 'main effects' was used to deter-
mine the importance of uPA, PAI-i and PAI-2 relative to
known classical prognostic factors (Cox, 1972). Table I pre-
sents the patient characteristics candidates for inclusion in
the Cox model. It should be noted that variables with more
than two outcome states were recoded using dummy
variables. In addition to these variables, the potential for
interaction between uPA, PAI-I and PAI-2 was evaluated in
a second Cox model, the 'interactive' model. The two models
were then compared using Akaike's criterion (Akaike, 1974;
Lawleff & Singhal, 1987a,b) which gives the best-fit model as
the one with minimum AIC (Akaike information criterion),
defined as: AIC =-2 log (likelihood) + 2 (number of
parameters).
Results
The distribution ofclinical, histological and biological factors
in the overall study population is shown in Table I. Addi-
Table I Description of the population and results of the univariate prognostic analysis
Number of Number of Number of
Factor patients events (%) P-values metastases (%) P-values
Age
<50 years
50-64 years
>64 years
Menopausal status
Premenopausal
Post-menopausal
Stage
II II
Clinical tumour size (mm)
<34
.34
Macroscopic tumour size (mm)
<29
.29
Path. axillary lymph nodes
0
1-3
>3
Scarff, Bloom and Richardson
grade
I
II
III
Oestrogen receptor level
< 10 fmol mg-' protein
> 10 fmol mg-' protein
Progesterone receptor level
<10 fmol mg-' protein
>10 fmol mg-' protein
uPA status
uPA - < 0.52 ng mg ' protein
uPA + >0.52 ng mg-' protein
PAI-I status
PAI-I - < 3 ng mg' protein
PAI-i + >3 ng mg protein
PAI-2 status
PAI-2 - < 14.5 ng mg-' protein
PAI-1+ >14.5 ng mg- protein
Combination
PAI-I - PAI-2 -
PAI-i - PAI-2 +
PAI-i + PAI-2 -
PAI-I + PAI-2 +
118 34 (29)
119 37 (31)
77 20 (26)
141 38 (27)
173 53 (31)
55
219
40
157
157
221
93
146
98
70
13 (24)
61(28)
17 (42)
35 (22)
56 (35)
56 (25)
35 (38)
32
25
34
30
199
85
95
219
137
177
214
100
231
83
271
43
205
26
66
17
(22)
(25)
(48)
6 (20)
61 (31)
24 (28)
29 (30)
62 (28)
45 (33)
46 (26)
55 (25)
36 (35)
60 (26)
31 (37)
85 (31)
6 (14)
56 (27)
4 (15)
29 (44)
2 (12)
0.8 30 (25)
30 (25)
18 (23)
0.2 34 (24)
44 (26)
0.04 10 (18)
52 (24)
16 (40)
0.005 27 (17)
51 (32)
0.01 46 (21)
32 (34)
<0.0005 24 (16)
21 (21)
33 (47)
0.5 4 (13)
51(26)
23 (27)
0.6 28 (29)
50 (23)
0.2 40 (29)
38 (21)
0.06 46 (21)
32 (32)
0.04 49 (21)
29 (35)
0.02 73 (27)
5 (12)
0.004 46 (22)
3 (11)
27 (41)
2 (12)
0.9
0.4
0.02
0.001
0.01
<0.0005
0.3
0.2
0.1
0.03
0.007
0.04
0.001400 C. BOUCHET et al.
Table II Distribution of uPA, PAI-1 and PAI-2 in the overall population of breast cancer
patients
Variable Median Mean Standard deviation Range Cut-off
uPA (ngmg-' protein) 0.32 0.48 0.53 0-4.4 0.52
PAI-1 (ngmg-' protein) 1.86 2.60 2.66 0-28.9 3
PAI-2 (ngmg-' protein) 2.72 8.70 19.18 0-171 14.5
tional details on the biological factors are presented in Table
II. The cut-off points were 0.52 ng per mg of protein for
uPA, 3 ng per mg of protein for PAI-I and 14.5 ng per mg of
protein for PAI-2.
Relation between uPA, PAI-I, PAI-2 and clinical and
histologicalfactors
uPA was not related to any clinical or histological variable.
High levels of uPA were related to high levels of PAI-l and
PAI-2 (P<0.0001, p =0.47, and P<0.001, p=0.35, respec-
tively). High levels of PAI-I and PAI-2 were related to
post-menopausal status (P = 0.008 and P<0.01 respectively).
Higher levels of PAI-I were related to SBR histological grade
IT and III (P<0.01) and showed borderline significance with
high values of PAI-2 (P = 0.06) (not shown).
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Univariate prognostic analysis in the overallpopulation (Table I)
High levels of uPA showed borderline significance with DFS
(P = 0.06) and were associated with MFS (P = 0.03). High
levels of PAI-I were associated with significantly shorter
DFS (P = 0.04) and MFS (P = 0.007) (Figure la). In con-
trast, high values of PAI-2 were associated with longer DFS
(P = 0.02) (Figure Tb) and MFS (P = 0.04). When PAI-I and
PAI-2 were combined, high levels of PAI-I and low levels of
PAI-2 correlated with poor DFS (P = 0.004) and MFS
(P = 0.001) (Figure lc).
Univariate prognostic analysis according to menopausal status
(Table III)
In premenopausal patients, uPA, PAI-I and PAI-2 levels
were not related to DFS or MFS. In post-menopausal
patients, high levels of uPA showed borderline significance
with DFS (P = 0.06) and were associated with shorter MFS
(P = 0.04). High levels of PAI-l were only associated with
shorter MFS (P = 0.02) (Figure 2a). In contrast, patients
with low levels of PAI-2 had shorter DFS (P = 0.02) and
MFS (P = 0.03) (Figure 2b). The combination of high levels
of PAI-l and low levels of PAI-2 correlated with shorter
DFS (P = 0.002) and MFS (P = 0.001) (Figure 2c).
Univariate prognostic analysis according to axillary node
status (Table IV)
In node-postive patients, uPA, PAI-I and PAI-2 were not
related to DFS or MFS. In node-negative patients, uPA was
not correlated with DFS or MFS. However, high levels of
PAI-I were associated with shorter DFS (P = 0.02) and MFS
(P = 0.0008). High levels of PAI-2 were only associated with
longer DFS. The combination of high levels of PAI-I and
low levels of PAI-2 was related to shorter DFS (P = 0.0008)
(Figure 3a) and MFS (P = 0.00005) (Figure 3b).
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Cox multivariate analysis ofclinical andhistologicalfactors
and uPA, PAI-I and PAI-2 in the overallpopulation (Table
V)
The two models took into account the main effects and
interactions respectively. With regard to DFS, the 'main
effects' model identified, in the following order, node involve-
ment, PAI-2 and PAI-I as independent variables. The
'interactive' model increased the individual prognostic value
Figure 1 Metastasis-free survival as a function of a, PAI-1; b,
PAI-2; and c, their association in the overall population. a,
Patients with high PAI-l levels had a significantly lower rate of
MFS than those with low levels. b, Patients with high PAI-2
levels had a significantly higher rate of MFS than those with low
levels. c, A particularly favourable prognostic group was
identified by an association between low PAI-i and high PAI-2
levels.
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Table III Univariate prognostic analysis according to DFS and MFS in post-menopausal patients (n = 173)
DFS MFS
Number of Number of Relative Number of Relative
Variable patients events (%) risk P-value metastases (%) risk P-value
UPA
<0.52ngmg- protein 119 31 (26) 1.0 0.06 25 (21) 1.00 0.04
>0.52ngmg- protein 54 22 (41) 1.70 19 (35) 1.86
PAI-I
<3ngmg' protein 117 31 (26) 1.00 0.1 24 (20) 1.00 0.02
>3 ngmg-' protein 56 22 (39) 1.56 20 (36) 1.91
PAI-2
< 14.5 ng mg' protein 142 49 (35) 1.00 0.02 41 (29) 1.00 0.03
>14.5ngmg' protein 31 4 (13) 0.32 3 (9) 0.30
Combination
PAI-1 - PAI-2 - 100 28 (28) 1.00 0.002 22 (22) 1.00 0.001
PAT-I - PAI-2 + 17 3 (18) 0.62 2 (12) 0.56
PAI-1 + PAI-2- 42 21 (50) 2.12 19 (45) 2.54
PAI-1 + PAI-2 + 14 1 (7) 0.20 1 (7) 0.27
Table IV Univariate prognostic analysis according to DFS and MFS in axillary node-negative patients (n = 146)
DFS MFS
Number of Number of Relative Number of Relative
Variable patients events (%) risk P-value metastases (%) risk P-value
UPA
<0.52ngmg-' protein 97 18 (18) 1.00 NS 12 (12) 1.00 NS
>0.52ngmg-' protein 49 14 (28) 1.59 12 (24) 2.12
PAI-I
£3ngmg' protein 102 17 (16) 1.00 0.02 10 (10) 1.00 0.0008
>3ngmg-' protein 44 15 (34) 2.22 14 (32) 3.64
PAI-2
< 14.5ngmg-' protein 121 31 (26) 1.00 0.02 23 (19) 1.00 NS
> 14.5 ngmg-' protein 25 1 (4) 0.13 1 (4) 0.19
Combination
PAI-1-PAI-2- 90 17 (19) 1.00 0.0008 10 (11) 1.00 0.00005
PAI-1-PAI-2 + 12 0 (0) 0 0 (0) 0
PAI-I + PAI-2 - 31 14 (45) 2.85 13 (42) 4.66
PAI-I + PAI-2 + 13 1 (8) 0.36 1 (8) 0.64
of PAI-I and PAI-2 by identifying a subpopulation with a
particularly poor prognosis, in which elevated PAI-I levels
were associated with low PAI-2 levels. With regard to MFS,
the main effects model identified, in the following order, node
involvement, PAI-1, clinical tumour size and PAI-2 as
independent variables. The 'interactive' model identified a
subpopulation with a particularly poor prognosis, in which
elevated PAI-I levels were associated with low PAI-2 levels,
as for DFS. According to Akaike's criterion, the interactive
model was equivalent to the 'main effects' model.
Cox multivariate analysis ofclinical andhistologicalfactors
and uPA, PAI-I and PAI-2 according to menopausal status
(Table VI)
In the premenopausal patients, macroscopic tumour size was
the only variable associated with DFS (P = 0.005). For MFS,
the only independent variable was node involvement
(P = 0.004) (not shown).
In the post-menopausal patients, the 'main effects' model
identified, in the following order, node involvement, uPA and
PAI-2 as independent variables for DFS. When interactions
were taken into account, the prognostic value of uPA and
PAI-2 was increased, identifying a subpopulation with a
particularly poor prognosis, in which high levels of uPA were
associated with low levels of PAI-2. With regard to MFS, the
'main effects' model identified, in the following order, uPA,
PAI-2, clinical tumour size and PAI-I as independent
variables. The 'interactive' model increased the individual
prognostic value of uPA and PAI-2, identifying a subpopula-
tion with a particularly poor prognosis, in which high levels
of uPA were associated with low levels of PAI-2.
Cox multivariate analysis ofclinical andhistologicalfactors
and uPA, PAI-i and PAI-2 according to axillary node status
(Table VII)
In the patients with node involvement, only the number of
affected nodes was selected by the Cox model, both for DFS
(P = 0.0008) and for MFS (P = 0.0002). This also held true
for DFS (P = 0.0008) when the interactions between the
relevant variables were taken into account. The 'interactive'
model identified an MFS population in which low levels of
PAI-I were associated with low levels of uPA (P = 0.05); this
minimised the pejorative effect of node involvement, which
remained the most important factor (P = 0.0002) (not
shown).
In the patients free of lymph node involvement, the 'main
effects' model identified PAI-2 and PAI-I as independent
variables for MFS and DFS. Similarly, when interactions
were taken into account in the DFS and MFS models, the
prognostic value of PAI-2 and PAI-I was increased; a sub-
population was identified in which the prognosis was parti-
cularly poor and in which high levels of PAI-I were
associated with low levels of PAI-2.402 C. BOUCHET et al.
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Figure 3 a, Disease-free survival; and b, Metastasis-free survival
as a function of the association of PAI-i and PAI-2 in axillary
node-negative women. DFS and MFS were particularly good in
women with low PAI-i and high PAI-2 levels.
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Figure 2 Metastasis-free survival as a function of a, PAI-1; b,
PAI-2; and c, their association in post-menopausal women. a,
Patients with high PAI-l levels had a significantly lower rate of
MFS than those with low levels. b, Patients with high PAI-2
levels had a significantly higher rate of MFS than those with low
levels. c, A particularly favourable prognostic group was
identified by an association between high PAI-I and high PAI-2
levels.
Discussion
The involvement of uPA in the invasion and metastatic
mechanisms is well documented (De Bruin et al., 1987; Sap-
pino et al., 1987; Janicke et al., 1990; Quax et al., 1990;
Hollas et al., 1991), but the exact role of the two inhibitors
PAI-I and PAI-2 is less well known.
To better analyse their prognostic value, it is important to
evaluate the relative importance of these three parameters
and their interactions. To this end, we measured uPA, PAI-I
and PAI-2 antigen levels in a series of-314 breast cancer
specimens and studied their relationships with classic
parameters, as well as their prognostic value.
We confirmed that uPA and PAI-i were independent of
classical prognostic factors (Duffy et al., 1990; Janicke et al.,
1990; Grondhal-Hansen et al., 1992; Reilly et al., 1992), as
well as the strong relationship between uPA and PAI-I
(Reilly et al., 1992). We also confirmed the poor prognosis of
patients with tumours containing high levels of uPA and
PAI-I (Duffy et al., 1990; Janicke et al., 1990; Grondhal-
Hansen et al., 1992; Spyratos et al., 1992; Sumiyoshi et al.,
1992). In contrast, high levels of PAI-2 were associated with
a favourable prognosis not only in the overall population,
but also in the subgroup of post-menopausal women and
those with no node involvement. PAI-2, which has highest
affinity constant for uPA, appears to be a true inhibitor,
contrary to PAI-1. Sumiyoshi et al. (1992) reported that
PAI-2 levels were higher in node-negative patients, but did
not provide a prognostic analysis.
The correlation between uPA and PAI-I antigen levels
suggests one of two possibilities (Reilly et al., 1992): either
PAI-i is a defence mechanism against tumoral invasion that
has been inactivated at the time of analysis, or it plays a role
in plasminogen activation. Our results, showing a link
between high levels of PAI-I and a poor outcome, tend to
support the second hypothesis and to confirm the redun-
dancy of the information provided by PAI-I and uPA. PAI-i
could also be a marker of neovascularisation, as it is abun-
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Table V Cox multivariate analysis in 'main effects' model and 'interactive' model of clinical, histological and biological
factors in breast cancer in overall population (n = 314) for DFS and MFS
Regression Relative risk
Criterion Variable coefficient (95% CI) P-value
DFS 'Main effects' model
Node status: <3 vs >3 0.970 2.6 (1.7-4.0) <0.0001
PAI-2 - 0.956 0.4 (0.2-0.9) 0.02
PAI-I 0.554 1.7 (1.1-2.7) 0.02
'Interactive' model
Node status: <3 vs >3 0.868 2.4 (1.5-3.7) <0.0001
PAI-I + PAI-2 - 0.737 2.1 (1.3-3.3) 0.003
Clinical tumour size: <34 vs >34mm 0.451 1.6 (1.0-2.4) 0.04
MFS 'Main effects' model
Node status: <3 vs >3 1.066 2.9 (1.8-4.6) <0.0001
PAI-I 0.796 2.2 (1.4-3.5) 0.007
Clinical tumour size: <34 vs >34mm 0.577 1.8 (1.1-2.9) 0.02
PAI-2 -0.962 0.4 (0.2-1.0) 0.01
'Interactive' model
Node status: <3 vs >3 1.106 2.9 (1.8-4.6) <0.0001
PAI-I + PAI-2 - 0.920 2.5 (1.6-4.0) 0.0008
Clinical tumour size: <34 vs >34 mm 0.593 1.8 (1.1-2.9) 0.02
Table VI Cox multivariate analysis in 'main effects' model and 'interactive' model of clinical, histological and biological
factors in breast cancer in menopausal patients (n = 173) for DFS and MFS
Regression Relative risk
Criterion Variable coefficient (95% CI) P-value
DFS 'Main effects' model
Nodal status: <3 vs >3 1.028 2.8 (1.6-4.9) 0.0003
uPA 0.872 2.4 (1.4-4.2) 0.03
PAI-2 - 1.280 0.3 (0.1-0.8) 0.005
'Interactive' model
Nodal status: <3 vs >3 1.115 3.0 (1.7-5.3) 0.0003
UPA + PAI-2 - 0.992 2.7 (1.5-4.7) 0.001
MFS 'Main effects' model
Nodal status: <3 vs >3 1.147 3.1 (1.7-5.8) <0.0001
uPA 0.668 2.0 (1.0-3.8) 0.02
PAI-2 - 1.215 0.3 (0.1-1.0) 0.01
Clinical tumour size: <34 vs >34mm 0.892 2.4 (1.2-5.1) 0.04
PAI-I 0.725 2.1 (1.1-4.0) 0.04
'Interactive' model
Nodal status: negative vs positive 1.189 3.3 (1.8-6.0) <0.0001
UPA + PAI-2- 1.047 2.9 (1.5-5.3) 0.001
Clinical tumour size: <34 vs >34mm 0.720 2.1 (1.0-4.2) 0.04
Table VII Cox multivariate analysis in 'main effects' model and 'interactive' model of clinical,
histological and biological factors in breast cancer in axillary node-negative patients (n = 146) for
DFS and MFS
Regression Relative risk
Criterion Variable coefficient (95% CI) P-value
DFS 'Main effects' model
PAI-2 - 2.362 0.1 (0.0-0.7) 0.005
PAI-1 1.080 2.9 (1.5-5.9) 0.003
'Interactive' model
PAl-I + PAI-2- 1.263 3.5 (1.8-7.1) 0.0008
MFS 'Main effects' model
PAI-i 1.573 4.8 (2.1-10.9) 0.002
PAI-2 - 2.171 0.1 (0.0-0.9) 0.003
'Interactive' model
PAl-I + PAI-2- 1.706 5.5 (2.5-12.3) <0.0001
dantly secreted by endothelial cells (Loskutoff & Edginton,
1977).
The Cox model identified subgroups of patients at risk, in
whom low levels of PAI-2 were associated, on the one hand,
with high levels of PAI-1, both in the overall population and
in the node-negative patients, and, on the other hand, with
high levels of uPA in the post-menopausal women. The
significant association observed in the overall population was
in fact due to the subgroup of post-menopausal women and
node-negative women. Indeed, PAI-I and PAI-2 levels were404 C. BOUCHET et al.
linked to hormonal status: high levels of both proteins were
found preferentially in the post-menopausal women. Scarabin
et al. (1990) suggested that decreased oestrogen production
could influence PAI-I activity and reported that serum levels
ofPAI-I were elevated in post-menopausal women relative to
premenopausal women, reflecting a degree of control of PAI-
1 secretion by oestrogen.
If one analyses the populations studied by Duffy et al.
(1990), Janicke et al. (1991), Foekens et al. (1992) and
Janicke et al. (1993), it can be seen that the median follow-up
periods are very different (35, 25, 5 and 30 months respec-
tively). Discrepancies between the results of these studies and
our own can partly be explained by differences in the popula-
tions. In the study by Janicke et al. (1993) (a prospective
study) the proportion of premenopausal patients (36%) was
lower than in our work (45%). In addition, there were
differences in the treatment regimens (chemotherapy, hor-
mone therapy). In the study by Duffy et al. (1990), 69% of
the patients received adjuvant treatment, compared with 28%
in the study by Foekens et al. (1992) and 37% in our work.
The number of patients also varied considerably. Janicke et
al. (1991) studied respectively 54 and 50 patients with and
without node involvement. The numbers in our work were
168 and 146 respectively.
In addition, the choice of buffer (presence or absence of
Triton X-100) directly influences the uPA antigen level
measured (Schmitt et al., 1991). However, the comparative
study by Schmitt et al. (1991) showed no significant differ-
ence for PAI-I (median PAI-I = 1.0 ng per mg of protein
without Triton X-100 and median PAI-I = 0.95 ng per mg of
protein with Triton X-100). The influence of this ionic deter-
gent on PAI-2 levels is unknown, but the results of a pro-
spective study by Foucre et al. (1991) and those of our study
are similar for PAI-I and PAI-2, although Triton X-100 was
used only in the former.
The determination of the cut-off could be the reason for
the slight discrepancies between the various reported data.
However, in the case of PAI-1, if one compares the cut-offs
determined by Janicke et al. (1993) (2.18 ngper mg of pro-
tein) and our population (3.0 ng per mg ofprotein), there is a
certain similarity despite the use ofdifferent approaches. It is,
however, very difficult to compare the cut-offs in other series
given the lack of standardisation.
In situ hybridisation studies of colonic cancer (Pyke et al.,
1991a) have shown a very heterogeneous distribution of PAI-
1 within the tumour and an association with uPA in areas
showing no signs of breakdown, suggesting a protective effect
of PAI-1. In contrast, our results obtained with breast
tumour cytosols suggest no such protective effect, although
further analysis using the same approach as Pyke et al.
(199lb)will be necessary. Indeed, tumours contain a complex
mixture of epithelial cells, stromal cells and vascular
elements, which could lead to interactions with an influence
on tumour development.
The potential prognostic factors PAI-1 and PAI-2,
together with the PAI-I-PAI-2 and uPA-PAI-2 associa-
tions, add to an evolving list of biological markers of breast
cancer, including oestrogen and progesterone receptors,
epidermal growth factor (EGF) receptor, uPA and cathepsin
D (Spyratos et al., 1992). A better understanding of the
regulation of uPA and its receptor and inhibitors (PAI-I and
PAI-2) in breast carcinomas may lead to other ways of
intcrrupting tumour invasion and metastasis formation.
This work was supported by the Ligue Nationale de Lutte contre le
Cancer (Comite des Hauts-de-Seine).
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